Product information for a veterinary medicine has to work for readers who are not clinicians. A farmer calculating a dose for a group of animals, a veterinary nurse handling a cytotoxic preparation, a pet owner reading a leaflet at home. Regulation (EU) 2019/6 sets the content requirements, but the practical quality of the summary of product characteristics, the label and the package leaflet is what determines whether the product is used as authorised.
Why it carries more weight than in human medicine
Three differences matter. The person administering the product is frequently not a healthcare professional. The dose often has to be calculated by body weight, sometimes across a group of animals of varying size. And for food-producing species the withdrawal period, which appears nowhere in a human leaflet, is a food safety control that depends entirely on being read and followed.
The elements that cause most trouble
- Dosing instructions. A dose expressed in a way that requires arithmetic under field conditions will be miscalculated. Clarity here is a safety intervention.
- Withdrawal periods. These must be unambiguous, species-specific and commodity-specific. Ambiguity translates directly into residue risk.
- User safety warnings. Handling precautions written for a laboratory setting are not useful on a farm. They need to describe what the user should actually do.
- Target species and categories. Precision matters, because it defines the boundary beyond which use becomes cascade use or unlawful off-label use.
- Storage conditions. Realistic for the environments where the product will be kept.
Consistency across the set
The summary of product characteristics, the labelling and the package leaflet have to say the same thing. They also have to say the same thing as the entry in the Union Product Database and as the approved text in every language version. Divergence between these is one of the more common findings in portfolio reviews, and it usually originates in a variation that was implemented in one place and not propagated to the others.
Translation is a regulatory activity
For the Greek market, product information must be provided in Greek, and the quality of that translation is a compliance matter rather than a publishing one. Dose expressions, units, species terms and withdrawal statements are the highest-risk elements. Translation carried out without veterinary regulatory review is a reliable source of questions from the authority and, worse, of errors that survive into the field.
Special statements
Some authorisation routes require specific statements. Products authorised under Article 23 of Regulation (EU) 2019/6 for a limited market must state clearly in the summary of product characteristics that only a limited assessment of safety or efficacy was conducted due to a lack of comprehensive data. These statements are not optional and they shape how the product is perceived, so they should be planned for rather than discovered at approval.
How PQRA helps
PQRA prepares, reviews and maintains veterinary product information across the lifecycle, including Greek language versions, consistency checks across the SPC, label, leaflet and database records, and remediation of portfolios where versions have diverged. We treat translation as regulatory work, reviewed by people who understand what the text has to achieve in the field.
For a review of your veterinary product information, contact PQRA.
No responses yet